Journal article icon

Journal article

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - A randomized placebo-controlled trial

Abstract:

Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor canagliflozin lowered blood glucose, blood pressure, and body weight, with increased risk of urogenital infections in Phase 2 studies. Effects on macrovascular complications of diabetes remain to be determined. CANVAS is a double-blind, placebo-controlled trial designed to evaluate the effects of canagliflozin on the risk of cardiovascular ...

Expand abstract

Actions


Access Document


Publisher copy:
10.1016/j.ahj.2013.05.007

Authors


Expand authors...
Journal:
American Heart Journal
Volume:
166
Issue:
2
Publication date:
2013-08-05
DOI:
EISSN:
1097-6744
ISSN:
0002-8703
URN:
uuid:0a0163c0-7358-456a-885f-9cb3800dfb7e
Source identifiers:
417308
Local pid:
pubs:417308
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP